ANTARES PHARMA, INC.
Healthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | $184.0M | $33.1M | $23.3M | $63.6M | $54.5M | $52.2M |
| Operating income | $65.9M | $13.6M | $992,000 | −$4.1M | −$15.6M | −$24.1M |
| Net income | $46.3M | −$2.4M | −$5.5M | −$6.5M | −$16.7M | −$24.3M |
| Total assets | $257.5M | $212.5M | $132.8M | $88.3M | $74.3M | $66.3M |
| Total liabilities | $81.7M | $93.4M | $78.3M | $49.3M | $40.8M | $21.1M |
| Equity | $175.8M | $119.1M | $54.5M | $39.0M | $33.5M | $45.2M |
| EPS (diluted) | $0.26 | $0.33 | $-0.01 | $-0.04 | — | — |
| Shares out. | 168.2M | 165.6M | 160.5M | 156.8M | 155.2M | 154.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- 35.8%
- Net margin
- 25.2%
- Return on equity
- 26.3%
- Return on assets
- 18.0%
- Return on capital (ROCE)
- 33.2%
- Liabilities / assets
- 31.7%
- Debt / equity
- 0.47×
- Book value / share
- $1.05
- Revenue growth (YoY)
- 456.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- 4.68safe
- Accruals / assets
- 3.8%clean
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 7 good- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Debt acceleration / triggering event · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMay 24, 2022
- Entered a material agreement · Amended charter or bylawsApr 13, 2022
- Regulation FD disclosureMar 7, 2022
- Results of operationsMar 3, 2022
- Regulation FD disclosureJan 11, 2022
- Entered a material agreement · Regulation FD disclosureDec 16, 2021
- Results of operationsNov 4, 2021
- Entered a material agreement · Terminated a material agreement · New financial obligationNov 2, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.